Elekta (OTCMKTS:EKTAY) Trading Up 0.2% – Still a Buy?

Shares of Elekta AB (OTCMKTS:EKTAY) rose 0.2% during trading on Friday . The stock traded as high as $6.1085 and last traded at $6.1085. Approximately 2,000 shares changed hands during trading, a decline of 32% from the average daily volume of 2,934 shares. The stock had previously closed at $6.0940.

Wall Street Analysts Forecast Growth

Separately, Zacks Research raised Elekta from a “strong sell” rating to a “hold” rating in a report on Tuesday, September 16th. Three research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Elekta currently has an average rating of “Reduce”.

Elekta Stock Performance

The firm has a market capitalization of $2.25 billion, a price-to-earnings ratio of 87.28 and a beta of 1.04. The stock has a fifty day moving average price of $5.43 and a 200-day moving average price of $5.17. The company has a current ratio of 1.04, a quick ratio of 0.82 and a debt-to-equity ratio of 0.66.

Elekta (OTCMKTS:EKTAY) last released its earnings results on Wednesday, November 26th. The company reported $0.07 EPS for the quarter. The company had revenue of $427.85 million during the quarter, compared to analysts’ expectations of $436.91 million. Elekta had a return on equity of 12.14% and a net margin of 1.62%. As a group, analysts anticipate that Elekta AB will post 0.36 earnings per share for the current fiscal year.

About Elekta

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.